The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Both drugmakers have approached Biogen regarding a possible deal, The Wall Street Journal reported, citing people familiar with the matter.
The paper said those sources said the discussions were informal and preliminary, and they may not result in a deal — in part because Biogen may not be interested. However, a source told CNBC that Allergan is unlikely to pursue the deal.
In mid-July, CEO George Scangos said he would leave Biogen in the coming months, once his replacement was found. That news sparked speculation that Scangos' departure could be a trigger for the biotech to be acquired.
"Obviously I can't comment on that," Scangos told CNBC on July 21. "That wouldn't make any logical sense to me that because I'm leaving, the company is in play. We all believe, the board believes, I believe, the future is bright for Biogen."
Scangos had been at Biogen for the past six years. In May, the company announced plans to spin off its hemophilia business, and it is in the midst of restructuring program, begun last October to cut costs and narrow its focus on core areas.
When contacted by CNBC, Biogen had no comment.
Merck spokeswoman Lainie Keller said, "We don't comment on speculation."
Allergan spokesman Mark Marmur also declined comment, saying, "Allergan does not comment on market rumor or speculation."
BIIB 2016 Stock
— CNBC's Meg Tirrell contributed to this report.